Evidence map›Paper›PMID 39673122›Full record

ArticleClinical and translational medicine2024

Dynamic conditioning of porcine kidney grafts with extracellular vesicles derived from urine progenitor cells: A proof-of-concept study.

Perrine Burdeyron, Sébastien Giraud, Maryne Lepoittevin, Nina Jordan, Sonia Brishoual, Maïté Jacquard, Virginie Ameteau, Nadège Boildieu, Estelle Lemarie, Jonathan Daniel and 8 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Perrine BurdeyronUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Sébastien GiraudUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Maryne LepoittevinUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Nina JordanUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Sonia BrishoualUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Maïté JacquardUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Virginie AmeteauUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Nadège BoildieuUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Estelle LemarieUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Jonathan DanielUniversité de Bordeaux, Institut des Sciences Moléculaires UMR-5255, Talence, France.
Frédéric MartinsUniversité de Bordeaux, INSERM, PUMA (Transcriptome), Neurocentre Magendie, Bordeaux, France.
Nicolas MélisUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Marine CouéUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Raphaël ThuillierUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Henri LeuveninkDepartment of Surgery, Surgical Research Laboratory, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Luc PellerinUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Thierry HauetUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.
Clara SteichenUniversité de Poitiers, INSERM IRMETIST U1313, CHU de Poitiers, Service de Biochimie, Poitiers, France.ORCID 0000-0003-1201-4904

Funding

Centre Hospitalier Universitaire de PoitiersEuropean Union (Projet Handicap Biologie Santé 2015-2020)FEDER/CPER HABISAN of Nouvelle AquitaineFondation de l'Avenir pour la Recherche Médicale Appliquée AP-RM-18-006INSERMRégion Nouvelle AquitaineUniversité de Poitiers
6 · The paper itself

Abstract

: Among strategies to limit ischemia/reperfusion (IR) injuries in transplantation, cell therapy using stem cells to condition/repair transplanted organs appears promising. We hypothesized that using a cell therapy based on extracellular vesicles (EVs) derived from urine progenitor cells (UPCs) during hypothermic and normothermic machine perfusion can prevent IR-related kidney damage. We isolated and characterized porcine UPCs and their extracellular vesicles (EVs). Then these were used in an ex vivo porcine kidney preservation model. Kidneys were subjected to warm ischemia (32 min) and then preserved by hypothermic machine perfusion (HMP) for 24 h before 5 h of normothermic machine perfusion (NMP). Three groups were performed (n = 5-6): Group 1 (G1): HMP/vehicle + NMP/vehicle, Group 2 (G2): HMP/EVs + NMP/vehicle, Group 3 (G3): HMP/EVs + NMP/EVs. Porcine UPCs were successfully isolated from urine and fully characterized as well as their EVs which were found of expected size/phenotype. EVs injection during HMP alone, NMP alone, or both was feasible and safe and did not impact perfusion parameters. However, cell damage markers (LDH, ASAT) were decreased in G3 compared with G1, and G3 kidneys displayed a preserved tissue integrity with reduced tubular dilatation and inflammation notably. However, renal function indicators such as creatinine clearance measured for 5 h of normothermic perfusion or NGAL perfusate's level were not modified by EVs injection. Regarding perfusate analysis, metabolomic analyses and cytokine quantification showed an immunomodulation signature in G3 compared with G1 and highlighted potential metabolic targets. In vitro, EVs as well as perfusates from G3 partially recovered endothelial cell metabolic activity after hypoxia. Finally, RNA-seq performed on kidney biopsies showed different profiles between G1 and G3 with regulation of potential IR targets of EVs therapy. We showed the feasibility/efficacy of UPC-EVs for hypothermic/normothermic kidney conditioning before transplantation, paving the way for combining machine perfusion with EVs-based cell therapy for organ conditioning. HIGHLIGHTS: ·UPCs from porcine urine can be used to generate a cell therapy product based on extracellular vesicles (pUPC-EVs). ·pUPC-EVs injection during HMP and NMP decreases cell damage markers and has an immunomodulatory effect. ·pUPC-EVs-treated kidneys have distinct biochemical, metabolic, and transcriptomic profiles highlighting targets of interest. ·Our results pave the way for combining machine perfusion with EV-based cell therapy for kidney conditioning.

Indexed as

Extracellular VesiclesKidney TransplantationStem CellsAnimalsKidneyOrgan PreservationProof of Concept StudyReperfusion InjurySwineUrinecell therapyexosomesextracellular vesicleskidney preservationkidney transplantationmachine perfusionpreclinical porcine modelurine progenitor/stem cells

Identifiers

PMID39673122
PMCPMC11645449

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.